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Abstract: Bronchioloalveolar carcinoma (BAC) is a previously
uncommon subset of adenocarcinoma with unique epidemiology,
pathology, radiographic presentation, clinical features, and natural
history compared with other non-small cell lung cancer (NSCLC)
subtypes. Classically, BAC demonstrates a relatively slow growth
pattern and indolent clinical course. However, in a subset of patients,
rapid growth and death from bilateral diffuse consolidative disease
occurs within months of diagnosis or recurrence. Recent data sug-
gest that the incidence of BAC is increasing, notably in younger
nonsmoking women. The initial radiographic presentation of BAC
varies considerably, from single ground glass opacities (GGOs) or
nodules of mixed ground glass and solid attenuation to diffuse
consolidative or bilateral multinodular disease. The rising incidence
of BAC is also reflected in recent lung cancer screening studies
employing helical computed tomography (CT), where the differen-
tial diagnosis of GGOs includes not only BAC and overt adenocar-
cinoma, but inflammatory disease, focal fibrosis, and atypical ad-
enomatous hyperplasia. Because advanced-stage BAC presents as
measurable mass lesions in fewer than 50% of cases, determination
of radiographic response to therapy by standard criteria is often
difficult. Here, we review current data regarding the radiographic
imaging of BAC: its radiographic presentations in asymptomatic
early-stage and in advanced-stage disease, the functional imaging
characteristics of BAC, and challenges of response assessment,
including evolving opportunities for computer-assisted image anal-
ysis.
(J Thorac Oncol. 2006;1: S20–S26)
Bronchioloalveolar carcinoma (BAC) is a previously rarepathologic subtype of adenocarcinoma that seems to be
steadily increasing in incidence. In one report, BAC rose
fourfold during the period of 1955 to 1990.1 Compared with
other subtypes of non-small cell lung cancer (NSCLC), BAC
is characterized by a distinct clinical presentation, radio-
graphic appearance, and natural history.2 Further distinguish-
ing BAC from other types of NSCLC is a higher percentage
of women, a younger age distribution, and a higher incidence
in never-smokers.2 These differences raise the question of
whether BAC represents a separate entity with an epidemi-
ology distinct from that of other NSCLCs. In support of this
concept are marked similarities between BAC and ovine
pulmonary adenomatosis in sheep, caused by the Jaagsiekte
retrovirus.3 Whether the clinical course of BAC is different in
the various histologic subsets (pure BAC, mucinous or non-
mucinous; BAC with invasion; and adenocarcinoma with
BAC features) remains controversial.4 Within the context of
this review, the term BAC is used to encompass all histologic
subtypes.
OBSERVATIONS OF EARLY-STAGE BAC FROM
COMPUTED TOMOGRAPHY SCREENING
TRIALS
Data from several observational trials with computed
tomography (CT) screening are providing insights into CT
screening efficacy as well as reshaping our notions of the
morphology of early-stage lung cancer. At prevalence CT,
the rate of detection of noncalcified lung nodules of any
size varies from 5.1 to 51.4%, with the positive predictive
valve varying from 0.02 to 0.12.5–12 The rates of new lung
nodule detection decrease at incidence screens. Two obser-
vational trials have found that lung cancer detection is in-
creased three- to fourfold with CT relative to chest radiogra-
phy.6,9 Overall, CT detects smaller and more peripheral lung
cancers, with selective oversampling of adenocarcinoma by
two- to threefold.6–12 In Japanese population-based screening
trials, CT-detected lung cancers have been observed with
high or equal frequency in never-smokers relative to current
or former smokers, although information about secondhand
smoke is incomplete.8,11 Among never-smokers, BAC com-
prises up to 90% of the cancers.8
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Early focal BAC or adenocarcinoma has three morpho-
logic appearances on CT: 1) pure ground glass (GGO)/
nonsolid, appearing as hazy increased attenuation that does
not obscure the underlying bronchovascular markings; 2)
solid, in which the nodule attenuation completely obscures
the underlying bronchovascular markings; and 3) mixed/
semisolid, having both GGO and solid components.13,14
These three appearances on CT correspond roughly to a
biological range extending from benign lesions or BAC at
one end to invasive adenocarcinoma at the other.
Pure focal GGO can represent both malignant and
benign conditions, including focal inflammation, organizing
pneumonia, focal fibrosis, aryl hydrocarbon hydroxylase, and
adenocarcinoma (Figure 1). When malignant, pure GGOs
tend to represent a more biologically indolent neoplasm that
corresponds to the lower grades of the Noguchi classifica-
tion15–18 or to atypical adenomatous hyperplasia. Lesion size
roughly portends increasing histologic grade and biological
aggressiveness. Lesions larger than 1 cm are more commonly
malignant,19,20 particularly if they persist for several months
or increase in size on serial assessment, as discussed below.
Lesions of mixed attenuation, in which there is a solid
component within the GGO nodule, suggest increasing bio-
logical virulence. BAC exhibits a purely lepidic growth
pattern with proliferation of cells along the alveolar walls
absent stromal, vascular, or pleural invasion. Radiographic–
pathologic correlations have shown that with pure BAC
lesions having mixed attenuation on CT, the solid component
corresponds to areas of structural collapse of alveoli.21,22
Mixed lesions may also represent BAC with small invasive
foci and fibroblastic proliferation (Noguchi type C lesions or
mixed adenocarcinoma with BAC component), so the obser-
vation of a solid component increases the level of suspicion
for invasive adenocarcinoma. The relative size of the solid
component, or central fibrosis, seems to be an independent
prognostic indicator of tumor biology and correlates with
histologic factors of vascular invasion and lymph node in-
volvement as well as survival.23,24
With pure GGO or mixed-attenuation lesions, evolving
features on serial CT that suggest malignancy are: (a) an
overall increase in size of a GGO, (b) development of a solid
component within a GGO, or (c) an increase in the solid
component of a mixed-attenuation lesion20,25 (Figure 2);
these changes should generally prompt histologic sampling.
Finally, coarse spiculation is also observed with higher fre-
quency among malignant than benign nodules; in fact, spic-
ulation is reported to portend findings of lymph node metas-
tases and vascular invasion, and significantly predicts worse
survival in patients with adenocarcinoma26,27.
Table 1 provides some perspective on the degree of
overlap that exists between CT features, the World Health
Organization (WHO) classification of lung cancers, and the
Noguchi classification of adenocarcinomas.15,28 Although CT
features demonstrate a logical trend from less to more bio-
logically aggressive, overlap between categories of lung can-
cer type (and prognosis) exist, and CT alone is insufficient to
partition lesions into meaningful biological strata.
Although the majority of these CT data on BAC derive
from Japanese screening trials, a higher than anticipated
proportion of BAC histology has also been observed in CT
screening trials in the United States.29,30 For example, the
Mayo Spiral CT Screening Trial has detected lung cancer in
66 patients over a 4-year period.29 Of these, 12 (18%) were
BAC and 26 were adenocarcinoma. Of BAC, seven cases
appeared as pure GGOs, three had mixed attenuation, and two
were solid. The greater proportion of BAC identified by CT
screening in asymptomatic individuals is at variance with
findings from the Surveillance, Epidemiology and End Re-
sults program administered by the National Cancer Institute,
in which review of data collected during two decades (1979–
1998) suggests that although BAC is increasing in incidence,
it continues to represent only 4% of all NSCLC.31 Focal
GGOs are not visible on chest radiography by virtue of their
low attenuation; as such, CT screening may be identifying a
reservoir of preclinical lesions that will force revisions in the
prevalence and incidence data on BAC.
THE POTENTIAL FOR OVERDIAGNOSIS OF BAC
Overdiagnosis refers to a lung cancer that would not
lead to an individual’s death because of slow growth rate and
competing age-related risks for death. In the original Mayo
Lung Project, Fontana et al32 observed 206 lung cancers in
the screened group, but only 160 cancers in the control group.
They found a significantly better 5-year survival for the
screened group compared with the control group; however,
there was no difference in lung cancer mortality between the
two groups. Accordingly, 46 excess cancers were diagnosed
in the screened group compared with the control group,
representing a roughly 25% increase. Long-term follow-up
studies by Marcus et al33 have continued to show a survival
FIGURE 1. Axial CT scan with lung windows through the
upper lobes in a 79-year-old male with a former 50 pack-
year smoking history, having quit 29 years ago. A solitary,
ovoid-shaped 16  10-mm diameter GGO is visible in the
left upper lobe. A tiny, solid component is suggested along
the inferior border (arrow). There was no intrathoracic
lymphadenopathy. Percutaneous biopsy was suspicious for
neoplasm, prompting left upper lobectomy. At histology,
this proved to be an adenocarcinoma with mixed infiltrating
acinar pattern and more prominent bronchioloalveolar pat-
tern. The central scar measured less than 0.5 cm.
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benefit for the intensely screened group, with no significant
mortality benefit. Although controversial, one generally ac-
cepted reason for this difference is overdiagnosis of lung cancer.
Calculation of average lung cancer volume-doubling
times (VDT) may assist in addressing the issue of overdiag-
nosis. Most reports suggest VDTs in the 100- to 300-day
range for NSCLC based on differences in measured tumor
diameters over time. In a report by Usuda et al,34 86 adeno-
carcinomas had a geometric mean VDT of 163 days.
Yankelevitz et al35 analyzed the results of the Mayo Lung
Project and the Memorial Sloan Kettering Cancer Center
Screening trial, noting a mean VDT of 101 days in the Mayo
study and 144 days in the Memorial study. Only 4 of 87
cancers in those two trials had VDTs of more than 400 days.
With a VDT of 400 days, a 3-mm-diameter lesion would
require 7.7 years to increase in size to 15 mm in diameter.
The authors opined that a VDT of over 400 days would be
consistent with overdiagnosis.
Screening CT may potentiate the risk of overdiagnosis,
particularly in population-screening programs ongoing in
Japan, in which half of the reported lung cancers occur in
nonsmoking females and are stage I BAC or well-differenti-
ated adenocarcinomas. These cancers seem to have a distinc-
tively different biological behavior than cancers that are
diagnosed in smokers. Recently, 82 lung cancers were de-
tected during a 3-year period in a Japanese mass screening
program using helical CT. Serial CT scans in 61 cancers
permitted estimates of VDT.36 Cancers were classified into
three different types. The mean VDT of GGO lesions was
813 375 days, mean VDT of mixed-attenuation lesions was
457  260 days, and mean VDT of solid lesions was 149 
125 days, the latter being more typical of lung cancers
detected by earlier chest radiography screening trials. Among
the 61 cancers, 31 (50%) had VDTs of more than 340 days,
and 90% of these were invisible on chest radiographs, reflect-
ing the high proportion of biologically indolent neoplasms
FIGURE 2. Axial chest CT images from scans obtained 18 months apart in a 70-year-old male with a formerly heavy smoking
history. (A) Baseline image shows a poorly circumscribed 18-mm-diameter nodule of mixed attenuation containing GGO with
a small, central, solid component (arrow). There is an additional subtle area of pure GGO visible posteriorly. (B) At 18 months,
the solid and GGO components of the nodule have increased. A corresponding FDG-PET scan was negative. At resection, this
proved to be an adenocarcinoma with mixed bronchioloalveolar and invasive features, well differentiated. The posterior GGO
was focal fibrosis. Lymph node dissection was negative for neoplasm.
TABLE 1. Comparisons Between the World Health Organization and Noguchi
Classifications of Lung Cancer and Computed Tomography Appearances
World Health
Organization 1999 Noguchi
Computed
Tomography morphology
Lymph
Node involvement
AAH Pure GGO
Pure BAC, mucinous
and nonmucinous
A  Localized Pure GGO No
B  Alveolar collapse Solid component No
Mixed adeno  BAC C  Fibroblast proliferation 1Solid component Yes
D  Poorly differentiated 11Solid component Yes
E  Tubular
F  Papillary
AAH, atypical adenomatous hyperplasia; BAC, bronchioloalveolar cell carcinoma; GGO, ground glass opacity.
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that are CT detected. Twenty-seven adenocarcinomas had a
VDT of more than 450 days, of which 12 had a VDT of more
than 730 days. By the standard proposed by Yankelevitz et
al,35 27 (33%) of these 82 cancers would be considered
overdiagnosis. Several low-grade BAC lesions of GGO at-
tenuation have also been observed in the current Mayo CT
screening trial during a 3.5- to 4.5-year period, raising the
question of whether surgical resection is always the required
or appropriate treatment. More data on the biological behav-
ior of these lesions are needed.
IMAGING FEATURES OF ADVANCED BAC
In patients presenting outside the setting of lung cancer
screening, BAC presents a spectrum of radiographic features,
ranging from unifocal to multifocal disease (Figure 3). One
classification divides the radiographic spectrum of BAC into
three patterns: solitary nodules or masses, localized consoli-
dation, and multicentric or diffuse disease.37,38 Roughly 40%
of BAC have historically presented as a solitary nodule or
mass. These nodules share the features described above for
screening-detected BAC, although rarely, cavitation is ob-
served37; more commonly, GGO or solid lesions will contain
discrete bubble-like lucencies or pseudocavitations, corre-
sponding pathologically to patent bronchioles or air-contain-
ing spaces within neoplastic glands.38 About 30% of cases of
BAC present with localized consolidation containing air
bronchograms that may simulate pneumonia. This pattern is
most typical of mucinous BAC.39 On contrast-enhanced CT,
the consolidation is usually of lower attenuation than chest-
wall soft tissues because of mucin production, enabling
visualization of normally enhancing pulmonary vessels
within the consolidation termed the CT angiogram sign.40
Multicentric disease, consisting of multiple bilateral nodules
or consolidations, is observed in about 30% of patients and is
associated with a worse prognosis than is localized disease.
Associated findings in BAC may include pleural effusions
(1–10%), atelectasis (3%), and, rarely, pneumothorax. Hilar
or mediastinal lymphadenopathy and distant metastases are
features of invasive adenocarcinoma with BAC features.37–48
METABOLIC IMAGING WITH POSITRON
EMISSION TOMOGRAPHY
Although CT provides inferential information based on
exquisite morphologic detail about the biological behavior of
BAC, positron emission tomography (PET) using [18F]
fluoro-doxy-D-glucose (FDG) has gained wide acceptance as
a means of distinguishing benign from malignant lung lesions
based on the premise of higher glucose metabolism of ma-
lignant tissues. The peak standardized uptake value (SUV) is
calculated as a semiquantitative measure of increased FDG
uptake within an area of FDG accumulation.49
Although data for BAC are limited to small series, a
number of independent investigators have shown a high
false-negative rate of FDG-PET for identifying pure BAC,
particularly when focal, relating to relatively slow prolifera-
tion rates and the well-differentiated nature of the tumor.49–52
Higashi et al49 observed negative FDG-PET scans in four
(57%) of seven patients with BAC. Similarly, significantly
lower peak SUVs were found in nine patients with solitary
BAC relative to the SUVs of 39 patients with other types of
lung cancer.51 Heyneman and Patz52 studied 15 patients with
BAC, eight with solitary disease, and seven with multifocal
disease. Only 38% of patients with solitary BAC had a
positive PET scan, whereas 86% of patients with multifocal
disease had a positive scan. FDG uptake has also been shown
to correlate with prognosis, especially in adenocarcinoma, in
which a high SUV correlates with poorer survival53,54
Limited data regarding incorporating FDG-PET into
lung cancer screening suggest that patients with a focal
pulmonary abnormality by conventional imaging studies and
a negative PET scan can be observed closely to determine
interval growth or resolution of the lesion. BAC should be
considered in focal lesions that persist on follow-up CT
scans, independent of FDG-PET scan results, and histologic
sampling should be considered. Malignant neoplasms (in-
cluding BAC) that are negative on PET are likely to be well
differentiated, exhibit an indolent biology, and have little
propensity for regional lymphadenopathy or metastases. The
ultimate impact of surveillance of these lesions with CT to
determine growth rate is unknown.55,56
RESPONSE ASSESSMENT TO THERAPY AND
COMPUTER-ASSISTED IMAGE ANALYSIS
Response rate is one of the most important endpoints
for assessing the efficacy of anticancer treatments. Standard-
ized methods for assessing response, such as those developed
by the WHO, have been in place for many years and are
typically applied in clinical trials evaluating new therapeutic
FIGURE 3. (A) Soft-tissue and (B)
lung windows from a chest CT scan
in a 35-year-old male with multifo-
cal, mucinous BAC. (A) Soft-tissue
windows show the characteristic low
attenuation of the consolidations. (B)
Lung windows show multifocal areas
of GGO and solid attenuation bilater-
ally in the lungs. Within the regions
of malignant consolidation are scat-
tered discrete cavitations and
pseudocavities (arrows), representing
patent bronchioles and air-contain-
ing spaces within the tumor.
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agents, as well as in daily oncologic practice.57 These systems
classify cancer lesions as measurable, nonmeasurable, or
evaluable based on their imaging appearances. Until recently,
the greatest perpendicular bidimensional measurements of a
lesion had been considered optimal for basing determination
of response. In 1999, the National Cancer Institute (NCI)
proposed a modified system known as Response Evaluation
Criteria for Solid Tumors (RECIST), which requires only the
longest unidimensional diameter of tumor size.58 Although
this system simplifies response assessment and has been
shown to correlate equally well with patient outcomes in
comparison with bidimensional measurements, there remains
a high degree of observer variability. In one study of 33
patients in which lung cancers more than 1.5 cm were
independently evaluated by five radiologists, bidimensional
and unidimensional measurements were determined on CT
scans according to WHO and RECIST criteria. Analysis of
variance showed a significant difference among the readers in
the measurements of lung nodules.59 In this study, the prob-
ability of misclassifying a tumor as progression ranged from
30 to 43%.
Another shortcoming of RECIST is that treatment re-
sponse by anatomic criteria may not accurately reflect the
positive impact of therapy in some cancers, either for reasons
of nonmeasurable disease or because therapy may induce
growth arrest, which does not necessarily translate into di-
minished lesion size. Thus, in some cases, there may be a
divergence of response rate by RECIST or WHO criteria
from survival benefit. The former problem is particularly
applicable to multifocal BAC presenting as pneumonic con-
solidations or micronodular lesions. A recent clinical trial
conducted by the South West Oncology Group (SWOG),
S0126, evaluated the efficacy of gefitinib, an epidermal
growth factor receptor inhibitor, in patients with advanced-
stage BAC. Approximately 50% of the patients presented on
chest CT with diffuse lesions that were not measurable by
RECIST criteria (Table 2).60,61
Computer-assisted image analysis (CAIA) offers con-
siderable potential for overcoming the limitations of RECIST
in analyzing CT image data of patients with BAC and other
hard-to-measure cancers; investigations of such systems by
several research teams are underway. Here, we summarize
results achieved to date by Lau et al61 evaluating CAIA in
patients in the S0126 SWOG trial. As described above, BAC
is a good clinical model for testing CAIA because of the high
incidence of nonmeasurable lesions. To the extent possible,
CAIA was compared with RECIST for the endpoints of
response and was also correlated with progression-free and
overall survival.
The methodology for this first-generation CAIA, based
on the principles of measuring optical density or grayscale
attenuation in pixels has been presented elsewhere and is
summarized briefly here.61 CT scans from 78 patients were
submitted as high-quality films, digitized with a laser film
digitizer, processed by an algorithm, and submitted to math-
ematical calculation of two- and three-dimensional size.
To demonstrate the applicability of this CAIA program,
an example of patient response to gefitinib is shown in pre-
and posttreatment CT scans (Figure 4). The two-dimensional
tumor size before treatment was 123 (Figure 4A); after
treatment, it was 86 (Figure 4B), representing a 30% decrease
[(123  86)/123  100]. Using this method, treatment
response to gefitinib in 78 advanced-stage BAC patients
enrolled in S0126 was determined (Table 3).61 Whereas these
preliminary data provide the basis for further evaluation of
CAIA in response assessment of BAC and other solid tumors,
this first-generation methodology involves multiple manual
steps, and there are technical hurdles in standardization of
TABLE 2. Radiographic Presentation of Patients on the
S0126 Trial
Radiographic Features Number of Patients
Consolidations 45 (40%)
Mass/consolidations 32 (32%)
Nodule 1 cm 22 (20%)
Nodule 1 cm 8 (7%)
Pleural effusion 1 (1%)
Total 111 (100%)
FIGURE 4. CT images showing pretreatment (A) and posttreatment (B) responses to gefitinib in a patient in the S0126
SWOG trial using the CAIA program.61 The two-dimensional tumor size before treatment was 123; after treatment, it was 86,
representing a 30% decrease [(123  86)/123  100]. In addition, there was a substantial decrease in attenuation of the tu-
mor after treatment. In the future, response assessment may be routinely quantifiable based on imaging-based features,
through the use of standardized software platforms.
Gandara et al Journal of Thoracic Oncology • Vol. 1, No. 9, November Supplement 2006
Copyright © 2006 by the International Association for the Study of Lung CancerS24
background variation and spatial calibration among CT scans.
Second-generation CAIA systems currently undergoing eval-
uation by Lau et al62 using ImageJ, a public-domain Java
image-processing program developed at the Research Ser-
vices Branch, National Institute of Mental Health, Bethesda,
Maryland, by W. Rashband.
FUTURE DIRECTIONS
Although FDG-PET complements conventional nonin-
vasive imaging, FDG remains a relatively nonselective im-
aging agent for lung cancer and, specifically, BAC. However,
PET does provide a paradigm for tumor imaging by tran-
scending traditional anatomic approaches. It therefore has the
potential to elucidate specific metabolic properties of the
tumor. Several experimental studies in this area are just
beginning to demonstrate the potential of molecular imaging
in the classification of tumors63–65 by exploiting imaging
patterns to produce a noninvasive tumor profile. This molec-
ular imaging description of a cancer can provide significant
diagnostic and prognostic information, enabling better pre-
diction of tumor biology and determination of the appropriate
therapeutic regimen. As we gain greater sophistication with
targeted imaging agents for PET and other modalities such as
magnetic resonance imaging, multimodality imaging that
integrates morphologic- and physiologic-feature analysis will
become a mainstay in oncologic diagnosis and response
assessment.
Additional progress in response assessment will neces-
sarily entail close coordination between all participants in the
multidisciplinary arena of oncology: basic scientists, infor-
maticians, clinician scientists, and radiologists. The ability to
compare data across trials will require greater standardization
of the vocabulary of radiographic response assessment, re-
porting guidelines, and agreement on the standards for image
acquisition, storage, and transmission. These standards are
predicated on the specific interpretation tasks, including the
determination of metabolic alterations, contrast uptake char-
acteristics, texture analyses, and how advanced CT, magnetic
resonance, and PET instrumentation can best provide that
data. In addition, the necessary resources for imaging re-
search must be created and maintained, including the devel-
opment of imaging data repositories enriched with clinico-
pathologic and molecular data to support prospective research
in the rapidly evolving field of oncology pharmacogenetics.
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